Solve the predictive-accuracy bottleneck. Spend wet-lab only on candidates that earned it.
Industry HTS already screens millions of compounds. The real bottleneck isn't throughput — it's that only ~7.9%[4] of compounds entering Phase I reach approval, and a single approved drug still costs ~$2.6 billion[1] across ~10 years[1][3]. Most of that spend is wasted on candidates that should have been killed at L1 evidence. The agentic platform redirects wet-lab and clinical spend to the calibrated shortlist.
The bottleneck is predictive accuracy, not screening throughput.
The cost of bringing one new drug to market has climbed past $2.6 billion[1] over the last decade, with average development timelines exceeding 10 years[1][3] from first investigation to first patient. The reason isn't biology becoming harder. It also isn't a screening-throughput problem — industry HTS already screens millions of compounds per program. The reason is that most of the candidates that survive screening still fail in vivo or in the clinic for reasons that were predictable earlier in the pipeline.
Roughly 48% of programs that enter Phase I never reach Phase II[4], and only ~7.9%[4] of compounds entering Phase I ever reach approval. Each one of those failures arrived at the wet lab and the clinic with the full per-candidate spend already committed. Adding more capital adds more benches and more trials; it doesn't change which candidates are picked. That is why "10× more funding" hasn't produced "10× more cures" — the bottleneck isn't capital, it's which candidates the capital is spent on.
The structural problem. Conventional pipelines are built around the assumption that screening volume is the constraint. It isn't — not for the last decade. The constraint is whether the screen identifies the candidates that will translate to humans. The agentic platform attacks that second constraint with a calibrated audit layer.
Agents do the breadth. Humans commit on the calibrated shortlist.
The agentic platform surveys a candidate space of 104 to 106 per program. Capsids, targets, motifs, compounds, biomarkers, trial designs — whatever the program needs. Each candidate is named, ranked, and audited against the platform's evidence hierarchy and reasoning audit. The shortlist that emerges — typically fewer than 50 compounds per round, ranked by calibrated confidence with named failure modes — is what humans commit on.
Screen broad, pick on heuristics, fail late.
- Screening throughput: not the problem — industry HTS already does millions of compounds per program.
- Selection signal: heuristic medicinal-chemistry intuition + traditional QSAR; predictive of human translation only weakly.
- Cost: ~$2.6B per approved drug[1], with overall Phase I → approval probability around ~7.9%[4] — most spend lost to candidates that fail late.
- Failure mode: candidates that looked good early get the budget; the ones that should have been killed at L1 evidence still consume the lab.
Survey breadth in silico, commit wet-lab to a calibrated shortlist.
- Candidate space: 104–106 per program, surveyed continuously by 106+ agents.
- Selection signal: calibrated cross-domain validation + IBC reasoning audit; each candidate carries L1/L2/L3 evidence tags and named failure modes.
- Cost: structurally lower per validated lead — the wasteful candidates are killed at L1, not at Phase II.
- Failure mode: pre-registered kill criteria + reasoning audit catch contamination and over-fitting before the wet lab spends a dollar on the candidate.
The wet lab still happens. The clinical trial still happens. The regulator still reviews. For the candidates that earned it — not the ones that should have been killed at L1 evidence. That redistribution of where the wet-lab dollar lands is the cost-and-timeline compression.
Where the cost and timeline actually compress.
The popular framing of AI-in-pharma is "AI will make the lab faster." That's the wrong framing — it underestimates the savings. The savings come from not running the lab on the candidates that shouldn't have been there in the first place.
| Cost driver | Conventional pipeline | Atlas Bio agentic platform |
|---|---|---|
| Pre-clinical discovery | Tens to hundreds of millions, multi-year. Most spend lost to candidates that fail in vivo for reasons predictable in silico. | Engine-led survey at L1/L2 evidence; wet-lab spend reserved for the calibrated shortlist that passed reasoning audit + cross-domain validation. |
| Translation traps (mouse → human) | Discovered in Phase I or later, after substantial CMC and tox spend. Roughly 48% of programs that enter Phase I never reach Phase II[4]. | Translation probability scored at Stage 0; programs with low predicted translation fail at L2 audit, not at Phase I. |
| Phase III attrition | Roughly 42% of programs that reach Phase III fail to clear it[4][2]. Each failure carries hundreds of millions in sunk cost. | Pre-registered SHA-256 locks on prediction set; programs whose Phase II readouts deviate from pre-registered predictions trigger HITL review before advancing. |
| Real-world performance | Trial populations are systematically fitter and less comorbid than community populations — a well-documented external-validity gap[5]. Approved drugs underperform in clinic for systematic reasons. | RWE calibration multipliers continuously applied; predictions are adjusted for community vs trial population before commit. |
| Overall Phase I → approval probability | Only ~7.9% of compounds that enter Phase I reach approval[4]. | Calibrated shortlist is enriched before wet-lab commit, so the candidates that reach Phase I have already passed cross-domain validation + IBC audit. |
| Total cost per approved drug | ~$2.6 billion[1] (DiMasi et al. 2016 capitalized estimate; subsequent analyses cite higher figures) | Target: structurally lower — bounded by validated wet-lab and clinical work, not by failed candidates. |
| Total timeline to approval | ~10 years[1][3] from first investigation to first patient | Target: structurally compressed — broad-search stage compresses from years to days; wet-lab and clinical stages run on a higher-confidence shortlist. |
The irreplaceable commit.
<50compounds per round — the calibrated shortlist humans commit on.
The agentic platform does the broad search. The wet lab and the clinic remain. Your SMEs and partner teams own:
- Wet-lab execution on the shortlisted candidates — in vitro confirmation, GLP toxicology, CMC.
- NHP cohort design and biodistribution work, where translation traps still need physical interrogation.
- Clinical trial commitment — protocol design, IRB approval, operational rollout.
- Final go / no-go decisions under SME judgment, with the platform's audit trail as supporting evidence rather than substitute reasoning.
- Domain-specific interpretation of platform outputs — especially where the platform's L1/L2 evidence tags signal "we can't conclude this from data, you need to commit on judgment."
The agentic platform is not a replacement for clinical-grade human judgment. It is a redistribution of where that judgment is spent. The shortlist humans commit on is what the platform has named, ranked, and justified with named failure modes. The broad survey behind it is where conventional pipelines have been burning capital and timeline on candidates that should have been killed earlier.
The advantage is calibration-bound, not throughput-bound.
A raw "millions of candidates surveyed" claim is not the advantage — industry HTS does that already. A 104–106 candidate space surveyed with calibrated uncertainty, named failure modes, and L1/L2/L3 evidence tags on every claim — that is the advantage. Calibration without scale is the conventional pipeline. Scale without calibration is noise.
The 8 pillars of the methodology — agentic architecture, Human-in-the-Loop protocol, evidence hierarchy, pre-registration, IBC reasoning audit, cross-domain validation, RWE calibration, and the audit-of-the-audit mechanism — are what make the predictive claim trustworthy rather than aspirational. See the methodology operating system →
This combination of breadth + calibration is what no conventional life-science company can do at this cost basis. They have the wet labs and the regulatory experience. We have the agentic survey and the audit layer. Partnership models combine the two; competition models do not.
References
- DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal of Health Economics. 2016;47:20–33. doi:10.1016/j.jhealeco.2016.01.012 — Source for the $2.6B capitalized cost-per-approved-drug estimate and ~10-year average development timeline.
- Wong CH, Siah KW, Lo AW. Estimation of clinical trial success rates and related parameters. Biostatistics. 2019;20(2):273–286. doi:10.1093/biostatistics/kxx069 — Analysis of 406,038 trial entries across 21,143 compounds; widely-cited reference for phase-by-phase clinical attrition.
- Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. Clinical development success rates for investigational drugs. Nature Biotechnology. 2014;32(1):40–51. doi:10.1038/nbt.2786 — Phase-transition success rates across 7,372 clinical-development paths; corroborates the 10-year timeline figure and provides per-phase attrition baselines.
- BIO, Informa Pharma Intelligence, & QLS Advisors. Clinical Development Success Rates and Contributing Factors 2011–2020. Industry report. 2021. Phase I→II success ~52% (so ~48% attrition at Phase I); Phase III→NDA/BLA ~58% (~42% attrition); overall Phase I→approval ~7.9%.
- Kennedy-Martin T, Curtis S, Faries D, Robinson S, Johnston J. A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results. Trials. 2015;16:495. doi:10.1186/s13063-015-1023-4 — Systematic review documenting the well-known gap in fitness, comorbidity burden, and demographic representation between RCT participants and community populations.
Atlas Bio platform metrics (104–106 candidate space, <50 compounds advanced per round, 106+ agents) are internal characterizations of the agentic engine, not external benchmarks. Cost and timeline compression targets are forward-looking goals derived from the methodology, not validated outcomes.
Want to see what this looks like for your program?
Briefings start with a 30-minute scope call. Bring a candidate space, an indication, or a partnership question — we'll walk through how the agentic platform would size the search, name the shortlist, and where your team's judgment commits.
Contact Us →